![Safety and immunogenicity of seven COVID-19 vaccines as a third dose ( booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial - Safety and immunogenicity of seven COVID-19 vaccines as a third dose ( booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -](https://www.thelancet.com/cms/attachment/966d70c5-8395-4ea2-9a35-94dc18f2f550/gr1.gif)
Safety and immunogenicity of seven COVID-19 vaccines as a third dose ( booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -
Booster Shots and Additional Doses for COVID-19 Vaccines — What You Need to Know | Johns Hopkins Medicine
![Covid spring booster 2023: Everything you need to know - Department of Health and Social Care Media Centre Covid spring booster 2023: Everything you need to know - Department of Health and Social Care Media Centre](https://healthmedia.blog.gov.uk/wp-content/uploads/sites/169/2023/04/Blog_Official_Graphic-03-1-1.jpg)